Abstract: A Shigella vaccine preparation comprising 10E8-10E12 CFU of a live, genetically attenuated Shigella flexneri strain that comprises a chromosomal deletion of setBA and which is non-invasive as determined by the Sereny test and an in vitro invasion assay using HeLa cells, wherein the strain comprises an endogenous invasion plasmid that is genetically engineered to incorporate a heterologous expression construct expressing a pathogen-specific antigen.
Type:
Application
Filed:
September 24, 2021
Publication date:
November 23, 2023
Applicant:
EVELIQURE BIOTECHNOLOGIES GMBH
Inventors:
Eszter NAGY, Tamás HENICS, Petra GIRARDI, Irene NEUHAUSER, Shushan HARUTYUNYAN, Gábor NAGY, Valeria SZIJARTO
Abstract: A live attenuated Shigella vaccine, which is based on a rough Shigella strain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and a Shigella strain, which is a S. flexneri 2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutated Shigella invasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.
Type:
Grant
Filed:
September 5, 2013
Date of Patent:
August 15, 2017
Assignee:
EVELIQURE BIOTECHNOLOGIES GMBH
Inventors:
Gábor Nagy, Tamás Henics, Valeria Szijárto, Eszter Nagy
Abstract: A live attenuated Shigella vaccine, which is based on a rough Shigella strain lacking LPS O-antigen which is non-invasive through a mutation of the invasion plasmid, specifically for use in the immunoprophylaxis of a subject to prevent infectious diseases, preferably enteral disease, and a Shigella strain, which is a S. flexneri 2a strain with a deletion of the rfb F, ipa B and/or ipa C genes, as well as a recombinant plasmid vector based on a mutated Shigella invasion plasmid comprising a nucleotide sequence encoding at least one heterologous antigen, wherein the plasmid is mutated in at least one of the ipa B and/or ipa C genes.
Type:
Application
Filed:
September 5, 2013
Publication date:
September 3, 2015
Applicant:
EVELIQURE BIOTECHNOLOGIES GMBH
Inventors:
Gábor Nagy, Tamás Henics, Valeria Szijárto, Eszter Nagy